The FDA has approved Talicia (omeprazole magnesium, amoxicillin and rifabutin delayed-release capsules; RedHill Biopharma) for the treatment of Helicobacter pylori (H. pylori) infection in adults.
The researchers discovered significant differences and substantial heterogeneity in risk for GC among API subgroups. Substantial differences in all-cause survival among API subgroups were also observed.
The study researchers concluded that recommendations for Helicobacter pylori screening should also include patients who exhibit GERD symptoms only, irrespective of regional origin.
A recent review published in the journal Pharmacotherapy summarizes recommendations for the treatment of Helicobacter pylori infection in special patient populations.
The impact of eradicated Helicobacter pylori on the pediatric gastric microbial community structure shows restoration of bacterial diversity consistent with noninfected children in the same endemic region.
Type 2 diabetes was linked to an increased risk for gastric cancer (adjusted hazard ratio, 1.73). Stratified statistical analysis demonstrated a significantly higher risk for gastric cardia cancer (adjusted hazard ratio, 3.40) and a significantly increased risk in those with suboptimal glycemic control (adjusted hazard ratio, 1.68).
